Table 4.

National guidelines in force during the study period for patients with cancer and viral infections

Virus	Guidelines during study period			Contemporary guidelines
	ASCO	NCCN	AASLD	ASCO	NCCN	AASLD
HBV	Chronic HBV [7]: Start anti-HBV therapy before and continue during anticancer therapy, continue after anticancer therapy is completed. Past HBV [7]: For patients receiving anti-CD20 monoclonal antibody therapy, start anti-HBV therapy (or monitor) before and continue during anticancer therapy, continue after anticancer therapy is completed. For all other anticancer therapies, monitor and start anti-HBV therapy only if HBV reactivation occurs.	Chronic HBV [2, 9]: Start anti-HBV therapy before and continue during anticancer therapy, continue after anticancer therapy is completed. Past HBV [2, 9]: For patients receiving anti-CD20 monoclonal antibody therapy, start anti-HBV therapy (or monitor) before and continue during anticancer therapy, continue after anticancer therapy is completed.	Chronic HBV [8]: Start anti-HBV therapy before and continue during anticancer therapy, continue after anticancer therapy is completed.	Chronic HBV [1]: Same as guidelines during the study period. Optimal timing for anti-HBV therapy is not clear for patients with a solid tumor due to lack of strong data. Past HBV [1]: Same as guidelines during the study period.	Chronic HBV [2]: Same as guidelines during the study period. Past HBV [2]: Same as guidelines during the study period.	Chronic HBV [3]: Same as guidelines during the study period. Past HBV [3]: For patients receiving anti-CD20 monoclonal antibody therapy, start anti-HBV therapy (or monitor) before and continue during anticancer therapy, continue after anticancer therapy is completed. For all other anticancer therapies, monitor and start anti-HBV therapy only if HBV reactivation occurs.
HCV	Not available.	Start and complete DAA therapy before cancer therapy or after cancer therapy, not during cancer therapy. [2]	Not available.	Not applicable.	Same as guidelines during the study period. [2]	Not applicable.
HIV	Not available.	Select ART cautiously due to potential drug-drug interactions, start and continue during anticancer therapy. [2]	Not applicable.	Not applicable.	Same as guidelines during the study period. [4]	Not applicable.

AASLD, American Association for the Study of Liver Diseases; ART, antiretroviral therapy; ASCO, American Society of Clinical Oncology; DAA, direct-acting antiviral; HBV, hepatitis B virus; HCV, hepatitis C virus; NCCN, National Comprehensive Cancer Network